Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
People painting this up with over 300k shares.
Financials are out. $2.3m in revs.
So would it make you feel better if they removed Christopher Street from that wholly owned subsidiary list and listed it under a new 'Partners' section? At the end of the day, it doesn't change anything businesswise.
UPZS did not purchase anything. They have a licensing agreement whereby UPZS is creating a custom line of products through it's 3 wholly owned subsidiaries (Unique Pizza, Jose Madrid Salsa, & PopsyCakes) under the Christopher Street Products brand name aka Christopher Street LLC.
They won't list Christopher Street as a wholly owned subsidiary because it isn't a wholly owned subsidiary of UPZS. The PR's clearly state that Christopher Street and UPZS have a partnership and licensing agreement. Why are you getting confused about all of this wholly owned subsidiary talk? Where did you get that info from?
You need to brush up on your business education. A company's business name can and will often be different from it's trade name. A trade name or doing business as (DBA) name can be changed at a moments notice and doesn't have to be registered as an Inc, LLC, or Corp and won't be found on a business entity search with the SOS.
https://www.patriotsoftware.com/accounting/training/blog/business-name-or-trade-name-difference/
$8 per share buyout is the likely explanation.
If the $99,254 taken in 2016 isn't an income, than what shall we define it?
BEAUTIFUL CLOSE!!! +24.7%!!!
GO ONCX!!!!
No one is questioning the legitimacy of Novartis? We just like to use question marks at the end of every sentence?
IMO?
Novartis is a legitimate company? Look who's listed just below them on the Itor-ghs website for highlighted trials?
http://www.itor-ghs.org/pharmaceutical-industry.php
IMO
Novartis' LFA102 is not even close to the same as Oncolix' G129R (Prolanta).
LFA102 is a monoclonal antibody, which are antibodies produced by a single clone of cells or cell line and consisting of identical antibody molecules.
G129R (Prolanta) is a prolactin receptor antagonist with a single amino acid mutation, which substitutes the 129th position on the peptide chain.
G120R (Somavert) is a human growth hormone receptor antagonist with a single amino acid mutation, which substitutes the 120th position on the peptide chain.
Human growth hormone and prolactin are both pituitary hormones of the same cytokine receptor family. They share 49 of their amino acid residues in identical positions on the peptide chain.
Can you now see how Prolanta and Somavert are more closely related than Prolanta and LFA102? The Novartis method is inferior to Prolanta which has precedent from its sibling drug known as Somavert.
Wen Chen developed both Prolanta and Somavert in the same manner. LFA102 is a completely different method of action which Wen Chen has nothing to do with. This is like comparing marijuana to opiates in terms of pain relief. Different methods of action and different drugs.
IMO
Idk but it's clear they aren't making any money lol selling at this point just doesn't make any sense.
It is the exact same post as the one from the other day? Literally word for word the same?
IMO
That makes complete sense.
There's never been a pump or a dump?
IMO
I wouldn't call listing BioVectra as the contract manufacturer on their website as distancing themselves? The RESI conferences and JP Morgan conference are scam 3rd party promotion pump and dump conferences?
IMO
Does OTC Markets have it's own trading service now?
Nice 200k buy at the EOD.
Michael Redman has sold 2 biophama's which are still in existence today? How many failures does majority own GHS have? Zero?
IMO
Is it possible? To put a question inside of a question? How many about Oncolix questions can you fit into one sentence? These are serious questions? That we need answers to?
?IMO¿
Typical "con artist" resume?
IMO
Leonid Schneider a cartoonist and blogger?
https://medium.com/@schneiderleonid
IMO
Forbetterscience is a blog though and that blogger who owns that site is a cartoonist. Bwhahahahaha
Whatever crazy research you're doing makes me laugh, waste of time and effort. It does bring a smile to my face knowing someone is wasting a perfectly good Saturday doing so. Sood is an elite doctor of MD Anderson. If there was an issue, he would've been fired already.
IMO
And at the end of the day, no matter what you dig up on Anil Sood, he's still employed by MD Anderson and that's as legit as it gets. Oncolix is very lucky to have him on the advisory board.
IMO
Apparently DarkPulse Technologies is reverse merging into a company. Could this be the one?
AH news would be swell.
What are you trying to communicate to us?
It doesnt matter even a fraction of a percent if Wen Chen is an advisor or not. Prolanta has already been invented and under the ownership of Oncolix. The science and effectiveness of Prolanta is no way shape or form dependent upon Wen Chen's involvement. If Prolanta is a success, Wen Chen doesnt need to be involved as he will collect licensing royalties for as long as Prolanta is used as a treatment.
The answer is ZERO.
I agree! 60 minutes would love a story about an upcoming and promising cancer treatment! let's email them and see if they will run the story!
I wonder if he's been warned about any potential threatening and harassing phone calls or emails?
This is great news!!! Thanks for sharing this wonderful DD!!! Oncolix now has a member from MD Anderson as an advisor, that's awesome!!!
I guess so LOL
Prolanta inventor also invented Somavert!!!
Wen Chen (Prolanta Inventor) also invented Somavert which is known as G120R. Somavert was successfully brought through trials obtaining FDA approval and is now sold on the market by Pfizer. Somavert (G120R) is a growth hormone receptor antagonist. This drug was able to successfully inhibit growth hormone receptors to help patients who have growth hormone disorders.
Prolanta also known as G129R is Wen Chens other invention. He developed both G120R and G129R around the same time period using the exact same amino acid substitution method. These drugs are almost identical to each other.
The other interesting fact is that the structure of prolactin is similar to that of the structure of growth hormone.
Here's an article that contains information regarding the similarities of prolactin hormone and growth hormone:
https://link.springer.com/chapter/10.1007%2F978-1-4757-3600-7_7
So here you have 2 near identical drugs that are antagonists to 2 structurally similar pituiatry hormones. Antagonizing human prolactin may be effective in treating cancer because of its role in the presence and growth of cancerous tumors. The other issue with human prolactin hormone is that it is a major factor in humans becoming resistant to chemotherapy. If you can antagonize the human prolactin receptors, you can at the very least increase the efficacy of chemotherapy, which in and of itself would be a major breakthrough.
So knowing that we have 2 almost identical drugs working to antagonize structurally similar hormones, we can hypothesize that both would be almost similarly efficacious. One drug, Somavert, has already achieved FDA approval, and the other drug, Prolanta, has a strong probability to follow suit.
G129R is almost equal to G120R
IMO
***AMAZING INVESTMENT OPPORTUNITY***
At this point, getting Prolanta though phase I is just a formality. Prolanta is 99% the same drug as Somavert. If you want to get an idea of how we will perform in phase I, go look at the Somavert trials. The only question that matters and it is what we will find out from completing 2-3 trial phases is: Does antagonizing human prolactin receptors result in an effective cancer treatment as either a monotherapy or combination therapy with chemo?
Based on the data and research, it's pretty much a given that Prolanta will be an effective antagonist, and Dr Wen Chen has already demonstrated that G129R is a pure hPRL receptor antagonist. Does a pure prolactin receptor antagonist actually treat cancer? I don't think it's a coincidence that doctors and scientists have been trying to find an effective way to antagonize human prolactin for the past 20-30 years. They know it plays a major role in many cancers. G129R is the only pure antagonist being developed at the moment. Knowing how effective Somavert is at antagonizing hGH and how similar and related hGH is to hPRL, and that Prolanta is essentially the same drug as Somavert, the odds are pretty good here.
IMO
No one has been "ripped off". Retail traders are 99.9% the reason for the price action. Oncolix has been answering questions and has been keeping shareholders up to date on all of its current business practices and milestones.
BMAK getting pushed back. Good sign.
OMG the FDA too!? This could be bigger than Watergate. I'm actually rooting for this happen because we would probably make more money suing GHS and the federal government than we would from an FDA approval.
IMO